DALLAS, June 21, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring NMT Medical Inc. (Nasdaq:NMTI). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/NMTI
NMT Medical Inc. (NMTI) is a medical technology company that designs, develops, manufactures and markets implant technologies that enables interventional cardiologists to treat structural heart disease, through catheter-based procedures. During the year ended December 31, 2009, the Company's revenues were derived from sales of its CardioSEAL, STARFlex and BioSTAR products primarily in the United States, Europe and Latin America. It also re-sells third party products for use with the CardioSEAL, STARFlex and BioSTAR implant devices, vascular sizing balloons and sheaths. BioSTAR is the Company's bioabsorbable patent foramen ovale (PFO) implant and the biological closure technology. Its customers include hospitals, clinics and other healthcare centers.
Message Board Search for NMTI: http://www.boardcentral.com/boards/NMTI
In the report, the analyst notes:
"For the first quarter of 2010, NMTI reported a net loss of approximately $7.9 million, or $0.54 per share, compared with a net loss of approximately $3.8 million, or $0.29 per share, for the corresponding period in 2009. Cardiac septal repair implant sales in North America for the first quarter of 2010 were approximately $2.0 million compared with approximately $2.3 million in the first quarter of 2009. Implant sales outside of North America were approximately $1.0 million in the first quarter of 2010 compared with $1.2 million in the corresponding period of 2009.
"NMTI recently announced that it has received preliminary results for CLOSURE I, its patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) trial in the United States. CLOSURE I is the first fully enrolled, randomized clinical trial to evaluate the effectiveness of PFO treatment in preventing recurrent strokes and TIAs. Analysis of the data for CLOSURE I commenced in April 2010."
To read the entire report visit: www.microstockprofit.com/lp/NMTI
See what investors are saying about NMTI at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.